CTL works diligently with Cornell researchers and innovators by bringing their inventions from the lab to the marketplace. As Cornell’s technology commercialization office, we are exploring new ways to create business opportunities, launching new ventures, and helping to commercialize Cornell technologies. Learn more about CTL’s annual activities and metrics.
Commercializing
109
Licenses & Options
FY2020-2024:
477 Licenses & Options
$22 M
Revenue Generated
FY2020-2024:
$122M Revenue Generated
Venturing
10
New Startups Based on Cornell IP
$418.6 M
Funding Raised by Startups in FY24
- Neuralenz
- Kubbly
- BiaWear
- Anova Biomedical
- Astoria Biologica
- Carbon to Stone
- ExoPower
- Giant Biosystems
- Graphenode
- Sacyl Pharmaceuticals
FY2020-2024:
$2.3B Funding Raised by Startups
Protecting
169
US Non-Provisional Patent Applications
| Filed Location | 2020 | 2021 | 2022 | 2023 | 2024 |
| U.S. Provisional | 158 | 163 | 163 | 164 | 143 |
| U.S. Nonprovisional | 195 | 179 | 164 | 169 | 169 |
| International | 322 | 304 | 318 | 217 | 251 |
| Total | 675 | 646 | 645 | 550 | 544 |
107
US Issued Patents
| FY | 2020 | 2021 | 2022 | 2023 | 2024 |
| U.S. | 124 | 127 | 79 | 104 | 107 |
| International | 284 | 191 | 142 | 117 | 144 |
| Total | 408 | 318 | 221 | 221 | 251 |
Ideating
34
Educational Programs Offered
70
Office Hours
313
IP Disclosures
Recent News
REEgen, a Cornell spinout that engineers bacteria to extract rare earth elements from industrial waste with technology licensed from Cornell, will scale up at a new development on Ithaca’s South…
Cornell’s Center for Technology Licensing (CTL) has released its FY25 Technology Commercialization Report highlighting new startups, licensing activity, and the programs helping move research discoveries from the lab to real-world…
Researchers from Cornell-licensed startup Inso Biosciences and the University of Washington have developed a technology for isolating high-molecular-weight DNA and preparing libraries for nanopore sequencing directly from samples in a…
In September, the U.S. Food and Drug Administration formally approved elamipretide as a treatment for Barth syndrome under an expedited process for rare diseases. The achievement is the realization of a two-decade-long…
